Medical News

RSS

Cubist signs definitive agreement to acquire Adolor

Cubist Pharmaceuticals, Inc. and Adolor Corporation today announced that they have signed a definitive agreement under which Cubist will acquire all of the outstanding shares of Adolor for $4.25 per share in cash, or approximately $190 million on a fully-diluted basis, net of Adolor's third quarter 2011 cash balance.

24 Oct 2011

eCareSoft announces new channel partner for Puerto Rico, Virgin Islands

eCareSoft, Inc. announced today its new channel partner for Puerto Rico and the Virgin Islands, e-Meds Healthcare Information Solutions. e-Meds will represent eCareSoft's integrated clinical, financial and EHR technology for hospitals.

24 Oct 2011

SafeMinds praises UNEP's draft treaty ban on use of mercury in pharma products

SafeMinds applauds UNEP's draft treaty language which does not exempt the use of mercury in pharmaceutical products, including vaccines, from the global ban. Governmental regulators, public health officials and pharmaceutical companies have recognized that the toxicity of mercury in pharmaceutical and personal care products, to which people are directly exposed, justifies a preventive approach to minimize all exposures.

24 Oct 2011

Synergy commences plecanatide Phase II/III trial in chronic idiopathic constipation

Synergy Pharmaceuticals, Inc., a developer of new drugs to treat gastrointestinal (GI) disorders and diseases, today announced initiation of dosing of patients in a major Phase II/III clinical trial of plecanatide to treat chronic idiopathic constipation.

24 Oct 2011

NeCEN centre for electron microscopy to open in Leiden

NeCEN, a new high quality centre for electron microscopy, opens its doors in Leiden on October 27th. NeCEN has two of the most advanced cryo-transmission electron microscopes worldwide.

24 Oct 2011

Bioject receives FDA communication on use of jet injectors with flu vaccines

Bioject Medical Technologies Inc., a leading developer of needle-free drug delivery systems, today announced that the Food and Drug Administration (FDA) has issued a communication on the use of jet injectors with influenza vaccines.

24 Oct 2011

Top-line results from Exelixis' cabozantinib phase 3 trial on medullary thyroid cancer

Exelixis, Inc. today reported top-line results from the ongoing phase 3 clinical trial of cabozantinib in patients with advanced medullary thyroid cancer (MTC), known as the EXAM trial.

24 Oct 2011

Arrowhead acquires RNA therapeutics assets from Roche

Arrowhead Research Corporation, today announced that it has acquired RNA therapeutics assets from Roche including the state-of-the-art research site in Madison, WI.

24 Oct 2011

HealthWarehouse.com to provide prescription medications for WhiteGlove

HealthWarehouse.com, Inc., a leading VIPPS-accredited retail mail-order pharmacy, announced today that it will begin providing prescription medications for WhiteGlove Health, Inc., a leader in service-driven healthcare.

24 Oct 2011

Elsevier / CPM announces availability of CarePoints Emergency

Elsevier / CPM Resource Center (CPM), a leader in developing clinical decision support tools for healthcare, announced today the availability of CPM CarePoints Emergency.

24 Oct 2011

U-M researchers to study new approach in halting downward spiral of diabetes

University of Michigan Health System researchers will use a $3.5 million federal grant to study a new approach in halting the downward spiral of diabetes.

24 Oct 2011

Encap Drug Delivery and Lena Nanoceutics to develop new drug delivery technology

Encap Drug Delivery and Lena Nanoceutics today announce a collaboration agreement to develop a new drug delivery technology (Nano-Capsules) which combines Lena’s proprietary nano-particle engineering technology with Encap’s liquid filled hard capsule technology.

24 Oct 2011

Mesoblast cleared to begin first phase 2 clinical trial for wet AMD

Regenerative medicine company Mesoblast Limited (ASX: MSB) today announced that it has received regulatory clearance from the Singapore Health Sciences Authority (HSA) to commence the first Phase 2 trial of its proprietary allogeneic (off-the-shelf) adult stem cell therapy for patients with proliferation of leaky blood vessels in the eyes – neovascular (“wet”) Age-related Macular Degeneration (AMD).

24 Oct 2011

Six prominent surgeons receive ACS' Honorary Fellowship

Honorary Fellowship in the American College of Surgeons (ACS) was awarded to six prominent surgeons from South Africa, England, Ireland, Italy, The Netherlands, and the People's Republic of China last night during Convocation ceremonies that preceded the official opening of the College's 97th Annual Clinical Congress.

24 Oct 2011

UCSF academic surgeon wins ACS' 2011 Distinguished Service Award

The Board of Regents of the American College of Surgeons (ACS) presented Mary H. McGrath, MD, MPH, FACS, of San Francisco, CA, with the College's 2011 Distinguished Service Award on October 23, during its Annual Clinical Congress in San Francisco.

24 Oct 2011

First public showcase of Ascom's Home Care Services

This summer Ascom Wireless Solutions launched their brand new line of Home Care Services - which is now getting ready for its first public showcase. In a couple of weeks attendees at Manchester's Healthcare Estates Exhibition will get the first opportunity to experience innovations ready to redefine independent living.

24 Oct 2011

Mesoblast receives Singapore HSA regulatory clearance to begin wet AMD Phase 2 trial

Regenerative medicine company Mesoblast Limited today announced that it has received regulatory clearance from the Singapore Health Sciences Authority (HSA) to commence the first Phase 2 trial of its proprietary allogeneic (off-the-shelf) adult stem cell therapy for patients with proliferation of leaky blood vessels in the eyes – neovascular Age-related Macular Degeneration.

24 Oct 2011

Mirna, Silence enter agreement to assess delivery systems for novel microRNAs

Silence Therapeutics plc, a leading RNA interference (RNAi) therapeutics company, today announced that it has entered into an agreement with Mirna Therapeutics Inc., a biopharmaceutical company pioneering microRNA-based therapeutics for cancer, to assess the delivery capabilities of Silence's proprietary AtuPLEX and DBTC delivery systems for Mirna's novel microRNAs.

24 Oct 2011

FDA accepts Ironwood and Forest Laboratories' linaclotide NDA for review

Ironwood Pharmaceuticals, Inc. and Forest Laboratories, Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for linaclotide for the treatment of irritable bowel syndrome with constipation (IBS-C) and chronic constipation.

24 Oct 2011

SCI patients with autonomic dysfunction more likely to develop heart disease

New research from the Heart and Stroke Foundation and the Christopher and Dana Reeve Foundation may help explain why people with spinal cord injury (SCI) have a higher risk of developing heart disease.

24 Oct 2011